Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma

被引：0

作者：

Liu, Yang ^{[1
]}

Yan, Zhiling ^{[2
]}

Wu, Qingyun ^{[2
]}

Chen, Chong ^{[2
]}

Cao, Jiang ^{[2
]}

Li, Zhenyu ^{[2
]}

Xu, Kailin ^{[2
]}

机构：

[1] Xuzhou Med Univ, Dept Hematol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China

[2] Xuzhou Med Univ, Blood Dis Inst, Xuzhou, Jiangsu, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-029

引用

页码：S49 / S49

页数：1

共 50 条

[31] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Saha, Aditi
Jhaveri, Khushali
Sarfraz, Humaira
Chavez, Julio C.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, : 869 - 876
[32] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Saha, Aditi
Jhaveri, Khushali
Sarfraz, Humaira
Chavez, Julio C.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2023,
[33] Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy
Thibaud, Santiago
Mia, Babu
Van Oekelen, Oliver
Mouhieddine, Tarek H.
Schaniel, Christoph
Ghodke-Puranik, Yogita
Aleman, Adolfo
Upadhyaya, Bhaskar
Lancman, Guido
Lagana, Alessandro
Richard, Shambavi
Rossi, Adriana
Chari, Ajai
Sanchez, Larysa
Rodriguez, Cesar
Cho, Hearn J.
Richter, Joshua
Hoffman, Ronald
Jagannath, Sundar
Parekh, Samir
BLOOD, 2022, 140
[34] High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma
Zhang, Xian
Wang, Lin
Yang, Junfang
Li, Jingjing
Liu, Hongxing
Li, Jianqiang
Lu, Peihua
BLOOD, 2023, 142
[35] CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity
Krejci, Martin
Adam, Zdenek
Krejci, Marta
Pour, Ludek
Sandecka, Viera
Stork, Martin
NEOPLASMA, 2022, 69 (05) : 1008 - 1018
[36] Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
Yao, Xin
Zhu, Shigui
Huang, Jiaqi
Qu, Xiaoyan
Zhu, Judy
Wei, Yutian
Lan, Liping
Lv, Xiaoteng
Wu, Junfeng
Wang, Rirfei
Yang, Dingzhu
Zheng, Chengxiao
Zhao, DiJun
Fan, Lei
Huang, Fei
Lu, Hua
Zhang, Chaocan
Chen, Cheng
Li, Yanfeng
Ren, Jiaqiang
Zhang, Li
Humphries, Michael
Li, Jianyong
Yao, Yihong
BLOOD, 2019, 134
[37] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sidana, Surbhi
Ahmed, Nausheen
Akhtar, Othman S.
Heim, Michael
Brazauskas, Ruta
Hansen, Doris K.
Ferreri, Christopher
Freeman, Ciara Louise L.
Afrough, Aimaz
Anderson, Larry D., Jr.
Dhakal, Binod
Dhanda, Devender
Gowda, Lohith
Hashmi, Hamza
Harrison, Melanie
Kitali, Amani
Mirza, Sayeef
Patel, Jinalben
Patwardhan, Pallavi
Usmani, Saad Z.
Patel, Krina K.
Ganguly, Siddhartha
Pasquini, Marcelo
BLOOD, 2023, 142
[38] A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
Zhang, Hua
Gao, Lei
Liu, Li
Wang, Jishi
Wang, Sanbin
Gao, Li
Zhang, Cheng
Liu, Yao
Kong, Peiyan
Liu, Jia
He, Jiaping
Han, Yu
Shi, Hua
He, Yan
Ye, Xun
Zhao, Yi
Cao, Wei
Shen, Lianjun
Zhang, Xi
BLOOD, 2019, 134
[39] The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
Rejeski, Kai
Hansen, Doris K.
Bansal, Radhika
Sesques, Pierre
Ailawadhi, Sikander
Logue, Jennifer M.
Freeman, Ciara L.
Alsina, Melissa
Theurich, Sebastian
Locke, Frederick L.
Bachy, Emmanuel
Jain, Michael D.
Lin, Yi
Subklewe, Marion
BLOOD, 2022, 140 : 7506 - 7508
[40] Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
Martin, Thomas G.
Madduri, Deepu
Pacaud, Lida
Usmani, Saad Z.
FUTURE ONCOLOGY, 2023, 19 (34) : 2297 - 2311

← 1 2 3 4 5 →